非酒精性脂肪性肝病的诊疗进展
Chinese Hepatology(2019)
Abstract
非酒精性脂肪性肝病(Non-Alcoholic Fatty Liver Disease,NAFLD)已经成为全世界慢性肝病的最常见原因,且在全球范围内的患病率不断增加,在我国发达地区,成人NAFLD患病率高达15%,成为我国慢性肝病的首要原因[1].该病的疾病谱包括非酒精性单纯性脂肪肝(non-alcoholic fatty liver,NAFL)、非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)以及NASH导致的肝硬化和肝癌.随着NAFLD发病率不断增加,不仅使其与肥胖、糖尿病等代谢综合征(metabolicsyndrome,MS)互为因果,恶性循环,还增加了心脑血管疾病及死亡的风险,同时NASH增加了肝细胞癌的风险,已成为欧美国家肝细胞肝癌的主要原因[2].NAFLD的早期诊断及药物干预治疗对控制疾病的发生发展至关重要.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined